ProPhase Labs, Inc.
PRPH evidence brief
What we can confirm
- BioSniper Score:
- 3.3 / 10
- Market Cap:
- $312K
- Lead Asset:
- be-smart (Preclinical)
What it means
What to watch
Prepared research question
What matters most for PRPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRPH
ProPhase Labs, Inc. is a diversified biotech and diagnostics company developing dietary supplements and prescription drugs through its ProPhase BioPharma subsidiary, while also offering whole genome sequencing services via DNA Complete and facing ongoing financial and legal challenges.
Key risk: Liquidity and capital risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$312K
Cash Runway
—
Lead Asset
be-smart (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for ProPhase Labs, Inc..
ProPhase Labs, Inc. is a diversified biotech and diagnostics company developing dietary supplements and prescription drugs through its ProPhase BioPharma subsidiary, while also offering whole genome sequencing services via DNA Complete and facing ongoing financial and legal challenges.
- ProPhase holds exclusive worldwide rights to develop and commercialize Equivir (dietary supplement) and Equivir G (Rx drug) under a license agreement with Global BioLife, Inc. [sec_mda · as of 2026-08-19]
- The company commenced patient enrollment in a randomized, placebo-controlled clinical trial of Equivir in March 2023 to evaluate its effect on immune system functions [sec_mda · as of 2026-08-19]
- ProPhase's wholly owned subsidiary DNA Complete offers whole genome sequencing products direct-to-consumers online, with plans to expand into retail stores and university research [sec_mda · as of 2026-06-30]
- As of June 30, 2026, the company reported cash & equivalents of $0.0M, total revenue of $1.0M, net income of -$3.1M, and shareholders' equity of -$3.1M [sec]
- A putative class action lawsuit (Portillo v. Nebula Genomics, Inc.) was filed in October 2024 alleging improper sharing of genetic information, and remains at the pleading stage [sec_mda · as of 2026-08-19]
What works
- ProPhase has exclusive worldwide rights to Equivir and Equivir G, with a clinical trial already underway, indicating a structured development pathway [sec_mda · as of 2026-08-19]
- The company plans to leverage its distribution network of over 40,000 FDM retail stores for Equivir commercialization, providing a potential market reach [sec_mda · as of 2026-08-19]
- DNA Complete's whole genome sequencing products are offered direct-to-consumer online, with expansion plans into retail and academic channels [sec_mda · as of 2026-06-30]
What to weigh
- ProPhase has a working capital deficit of $53.0 million as of March 31, 2026, and cash & equivalents of $0.0M as of June 30, 2026, indicating severe liquidity constraints [sec_mda · as of 2026-06-30][sec]
- The company faces a putative class action lawsuit under Illinois's Genetic Information Privacy Act, which could result in significant legal costs or damages [sec_mda · as of 2026-08-19]
- Equivir and Equivir G are still in early development (clinical trial ongoing for Equivir, preclinical for related candidates), with no guarantee of successful commercialization [sec_mda · as of 2026-08-19][pipeline]
From the filings
Quoted directly from source documents.
ProPhase has exclusive worldwide rights to Equivir and Equivir G under a license agreement with Global BioLife.
“We have exclusive worldwide rights to develop and commercialize Equivir (a dietary supplement candidate) and Equivir G (a Rx drug candidate) pursuant to a license agreement with Global BioLife, Inc.”
SEC MD&A · August 19, 2026
The company commenced a clinical trial for Equivir in March 2023.
“In March 2023, we commenced patient enrollment in a randomized, placebo-controlled clinical trial of Equivir”
SEC MD&A · August 19, 2026
ProPhase has a working capital deficit of $53.0 million as of March 31, 2026.
“Our working capital deficit was $53.0 million and $49.9 million as of March 31, 2026 and December 31, 2025, respectively.”
SEC MD&A · June 30, 2026
Risks & what to watch (3)›
Key risks
- Liquidity and capital risk — Cash & equivalents of $0.0M and working capital deficit of $53.0M as of March 31, 2026, raise going-concern doubts [sec][sec_mda · as of 2026-06-30]
- Legal risk from GIPA lawsuit — A putative class action under Illinois's Genetic Information Privacy Act could lead to significant liability [sec_mda · as of 2026-08-19]
- Clinical and regulatory risk — Equivir and Equivir G are in early stages; clinical failure or regulatory hurdles could impair value [sec_mda · as of 2026-08-19][pipeline]
What to watch
- Progress of the Equivir clinical trial and any interim results [sec_mda · as of 2026-08-19]
- Resolution or developments in the Portillo v. Nebula Genomics class action lawsuit [sec_mda · as of 2026-08-19]
- Ability to raise additional capital or secure financing to address working capital deficit [sec_mda · as of 2026-06-30]
- Commercialization milestones for DNA Complete's whole genome sequencing products [sec_mda · as of 2026-06-30]
Sources: Pipeline · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run ProPhase Labs, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ProPhase Labs, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$3M
Lead: Preclinical
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 30, 2026- % of float
- 0.7%
- Days to cover
- 0.1
- Shares short
- 30,023
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for ProPhase Labs, Inc.?
ProPhase Labs, Inc. is a diversified biotech and diagnostics company developing dietary supplements and prescription drugs through its ProPhase BioPharma subsidiary, while also offering whole genome sequencing services via DNA Complete and facing ongoing financial and legal challenges.
What is ProPhase Labs, Inc.'s lead drug candidate?
ProPhase Labs, Inc.'s most advanced tracked candidate is be-smart (Preclinical) for Early detection of progression from Barrett's esophagus to esophageal adenocarcinoma.
Who is the CEO of ProPhase Labs, Inc.?
Mr. Ted William Karkus is the chief executive officer of ProPhase Labs, Inc. (PRPH).
Where is ProPhase Labs, Inc. headquartered?
ProPhase Labs, Inc. (PRPH) is headquartered in Uniondale, NY, United States.
What therapeutic areas does ProPhase Labs, Inc. focus on?
ProPhase Labs, Inc. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.